索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]赵磊,张静,孟显东,等.吡非尼酮对心血管疾病的作用[J].国际心血管病杂志,2024,02:81-83，88.
点击复制

吡非尼酮对心血管疾病的作用(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2024年02期
页码:
81-83，88
栏目:
综述
出版日期:
2024-03-25

文章信息/Info

Title:
-
作者:
赵磊; 张静; 孟显东; 刘喜
010110 呼和浩特，内蒙古医科大学内蒙古临床医学院（赵磊）；010110 内蒙古医科大学研究生院（张静）；028006 通辽市科尔沁区第一人民医院心内科（孟显东）；010017 呼和浩特，内蒙古自治区人民医院心脏中心（刘喜）
Author(s):
-
关键词:
吡菲尼酮; 心肌纤维化; 抗炎治疗; 动脉粥样硬化; 心室重构
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2024.02.005
文献标识码:
-
摘要:
吡非尼酮（PFD）是首个用于治疗特发性肺纤维化（IPF）的小分子药物，可以通过抑制肺的纤维化反应及其他机制（如抗炎特性）减缓IPF的进展。有研究表明PFD具有抗动脉粥样硬化作用，同时可以改善心室重构，有效降低心律失常的发生。该文介绍PFD的药理作用和可能的作用机制，及其治疗心血管疾病的临床研究。
Abstract:
-

参考文献/References

[1] 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2021概要[J]. 中国循环杂志, 2022, 37(6):553-578.
[2] Poznyak AV, Bharadwaj D, Prasad G, et al. Renin-angiotensin system in pathogenesis of atherosclerosis and treatment of CVD[J]. Int J Mol Sci, 2021, 22(13):6702.
[3] Libby P. Inflammation in atherosclerosis—no longer a theory[J]. Clin Chem, 2021, 67(1):131-142.
[4] Smolgovsky S, Ibeh U, Tamayo TP, et al. Adding insult to injury—inflammation at the heart of cardiac fibrosis[J]. Cell Signal, 2021, 77:109828.
[5] Hisata S, Bando M, Homma S, et al. Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: a multicenter retrospective observational study in Japan[J]. Respir Investig, 2021, 59(6):819-826.
[6] Hwang H, Lee JK, Choi SM, et al. Efficacy of lower dose pirfenidone for idiopathic pulmonary fibrosis in real practice:a retrospective cohort study[J]. Korean J Intern Med, 2022, 37(2):366-376.
[7] Zhang YJ, Chen B. Silencing circ_0062389 alleviates cardiomyocyte apoptosis in heart failure rats via modulating TGF-β1/Smad3 signaling pathway[J]. Gene, 2021, 766:145154.
[8] Nathan SD, Albera C, Bradford WZ, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis[J]. Lancet Respir Med, 2017, 5(1):33-41.
[9] Aimo A, Spitaleri G, Nieri DR, et al. Pirfenidone for idiopathic pulmonary fibrosis and beyond[J]. Card Fail Rev, 2022, 8:e12.
[10] Bellaye PS, Burgy O, Bonniaud P, et al. HSP47: a potential target for fibrotic diseases and implications for therapy[J]. Expert Opin Ther Targets, 2021, 25(1):49-62.
[11] Capodanno D, Alfonso F, Levine GN, et al. ACC/AHA versus ESC guidelines on dualantiplatelet therapy: JACC guideline comparison[J]. J Am Coll Cardiol, 2018, 72(23):2915-2931.
[12] Bai T, Li MX, Liu YF, et al. Inhibition of ferroptosis alleviates atherosclerosis through attenuating lipid peroxidation and endothelial dysfunction in mouse aortic endothelial cell[J]. Free Radic Biol Med, 2020, 160:92-102.
[13] Misra HP, Rabideau C. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals[J]. Mol Cell Biochem, 2000, 204(1/2):119-126.
[14] Jenab A, Roghanian R, Emtiazi G. Bacterial natural compounds with anti-inflammatory and immunomodulatory properties (mini review)[J]. Drug Des Devel Ther, 2020, 14:3787-3801.
[15] Sethwala AM, Goh I, Amerena JV. Combating inflammation in cardiovascular disease[J]. Heart Lung Circ, 2021, 30(2):197-206.
[16] Mai WQ, Liao YH. Targeting IL-1β in the treatment of atherosclerosis[J]. Front Immunol, 2020, 11:589654.
[17] Shi Q, Liu XY, Bai YY, et al. In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion[J]. PLoS One, 2011, 6(11):e28134.
[18] Haybar H, Shokuhian M, Bagheri M, et al. Involvement of circulating inflammatory factors in prognosis and risk of cardiovascular disease[J]. J Mol Cell Cardiol, 2019, 132:110-119.
[19] Takahashi M. Role of NLRP3 inflammasome in cardiac inflammation and remodeling after myocardial infarction[J]. Biol Pharm Bull, 2019, 42(4):518-523.
[20] Wang YL, Wu YQ, Chen JW, et al. Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation[J]. Cardiology, 2013, 126(1):1-11.
[21] Patel S, Rauf A, Khan H, et al. Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies[J]. Biomed Pharmacother, 2017, 94:317-325.
[22] Yamazaki T, Yamashita N, Izumi Y, et al. The antifibrotic agent pirfenidone inhibits angiotensin Ⅱ-induced cardiac hypertrophy in mice[J]. Hypertens Res, 2012, 35(1):34-40.
[23] Li CM, Han R, Kang L, et al. Pirfenidone controls the feedback loop of the AT1R/p38 MAPK/renin-angiotensin system axis by regulating liver X receptor-α in myocardial infarction-induced cardiac fibrosis[J]. Sci Rep, 2017, 7:40523.
[24] 王志燕, 陈晨, 吕强, 等. 2021年ESC急慢性心力衰竭诊断与治疗指南解读[J]. 中华心血管病杂志, 2021, 49(12):1252-1255.
[25] McMurray JJ, Pfeffer MA. Heart failure[J]. Lancet, 2005, 365(9474):1877-1889.
[26] Van Erp C, Irwin NG, Hoey AJ. Long-term administration of pirfenidone improves cardiac function in mdx mice[J]. Muscle Nerve, 2006, 34(3):327-334.
[27] Lewis GA, Dodd S, Clayton D, et al. Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial[J]. Nat Med, 2021, 27(8):1477-1482.
[28] Glassberg MK, Nathan SD, Lin CY, et al. Cardiovascular risks, bleeding risks, and clinical events from 3 phase Ⅲ trials of pirfenidone in patients with idiopathic pulmonary fibrosis[J]. Adv Ther, 2019, 36(10):2910-2926.
[29] Di Palo KE, Heart F. Targets, and treatment[J]. Heart Fail Clin, 2020, 16(1):99-106.
[30] Mirkovic S, Seymour AM, Fenning A, et al. Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats[J]. Br J Pharmacol, 2002, 135(4):961-968.
[31] Brundel BJJM, Ai X, Hills MT, et al. Atrial fibrillation[J]. Nat Rev Dis Primers, 2022, 8(1):21.
[32] Sohns C, Marrouche NF. Atrial fibrillation and cardiac fibrosis[J]. Eur Heart J, 2020, 41(10):1123-1131.
[33] Lee KW, Everett TH4, Rahmutula D, et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure[J]. Circulation, 2006, 114(16):1703-1712.
[34] Nguyen DT, Ding CH, Wilson E, et al. Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias[J]. Heart Rhythm, 2010, 7(10):1438-1445.
[35] Ramos-Mondragón R, Galindo CA, García-Casta?eda M, et al. Chronic potentiation of cardiac L-type Ca2+ channels by pirfenidone[J]. Cardiovasc Res, 2012, 96(2):244-254.

备注/Memo

备注/Memo:
通信作者：刘喜， E-mail：Liuxi2594@163.com
更新日期/Last Update: 2024-03-25